Hepatic Transport

Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability

Volumn 40, Issue , 2009, Pages 277-332

  Maeda, Kazuya ^a   Suzuki, Hiroshi ^b   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Double transfectant; Drug drug interaction; Genetic polymorphism; Knockout mice; Prediction; Transcellular transport

Indexed keywords

FORECASTING;

DOUBLE TRANSFECTANT; DRUG-DRUG INTERACTIONS; GENETIC POLYMORPHISMS; KNOCKOUT MICE; TRANSCELLULAR TRANSPORT;

DRUG INTERACTIONS;

EID: 84969278217     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527623860.ch11     Document Type: Chapter

References (287)

1. Pauli-Magnus, C. and Meier, P.J. (2006) Hepatobiliary transporters and drug-induced cholestasis. Hepatology (Baltimore, Md.), 44, 778-787.
2. Shitara, Y., Horie, T. and Sugiyama, Y. (2006) Transporters as a determinant of drug clearance and tissue distribution. European Journal of Pharmaceutical Sciences, 27, 425-446.
3. Annaert, P., Swift, B., Lee, J.K. and Brouwer, K.L.R. (2007) Drug transport in the liver, in Drug Transporters (eds G. You and M.E. Morris), John Wiley & Sons, Inc., New Jersey, pp. 359-410.
4. Choudhuri, S. and Klaassen, C.D. (2006) Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. International Journal of Toxicology, 25, 231-259.
5. Kruh, G.D., Belinsky, M.G., Gallo, J.M. and Lee, K. (2007) Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis Reviews, 26, 5-14.
6. Borst, P., de Wolf, C.and van de Wetering, K. (2007) Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Archiv: European Journal of Physiology, 453, 661-673.
7. Hagenbuch, B. and Meier, P.J. (1994) Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. The Journal of Clinical Investigation, 93, 1326-1331.
8. Hagenbuch, B., Stieger, B., Foguet, M., Lubbert, H. and Meier, P.J. (1991) Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proceedings of the National Academy of Sciences of the United States of America, 88, 10629-10633.
9. Maeda, K., Kambara, M., Tian, Y., Hofmann, A.F. and Sugiyama, Y. (2006) Uptake of ursodeoxycholate and its conjugates by human hepatocytes: role of Na(+)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and oatp1B3 (OATP8). Molecular Pharmaceutics, 3, 70-77.
10. Eloranta, J. and Kullak-Ublick, G. (2007) Bile acid transporters, in Drug Transporters (eds G. You and M. Morris), John Wiley & Sons, Inc., New Jersey, pp. 201-222.
11. Meier, P.J. and Stieger, B. (2002) Bile salt transporters. Annual Review ofPhysiology, 64, 635-661.
12. Mita, S., Suzuki, H., Akita, H., Hayashi, H., Onuki, R., Hofmann, A.F. and Sugiyama, Y. (2006) Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep. American Journal ofPhysiology. Gastrointestinal and Liver Physiology, 290, G550-G556.
13. Meier, P.J., Eckhardt, U., Schroeder, A., Hagenbuch, B. and Stieger, B. (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology (Baltimore, Md.), 26, 1667-1677.
14. Friesema, E.C., Docter, R., Moerings, E.P., Stieger, B., Hagenbuch, B., Meier, P.J., Krenning, E.P., Hennemann, G. and Visser, T.J. (1999) Identificationofthyroid hormone transporters. Biochemical and Biophysical Research Communications, 254, 497-501.
15. Gundala, S., Wells, L.D., Milliano, M.T., Talkad, V., Luxon, B.A. and Neuschwander-Tetri, B.A. (2004) The hepatocellular bile acid transporter Ntcp facilitates uptake ofthe lethal mushroom toxin alpha-amanitin. Archives of Toxicology, 78, 68-73.
16. Ho, R.H., Tirona, R.G., Leake, B.F., Glaeser, H., Lee, W., Lemke, C.J., Wang, Y. and Kim, R.B. (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology, 130, 1793-1806.
17. Petzinger, E., Blumrich, M., Bruhl, B., Eckhardt, U., Follmann, W., Honscha, W., Horz, J.A., Muller, N., Nickau, L., Ottallah-Kolac, M., Platte, H.D., Schenk, A., Schuh, K., Schulz, K. and Schulz, S. (1996) What we have learned about bumetanide and the concept of multispecific bile acid/drug transporters from the liver. Journal of Hepatology, 24 (Suppl. 1), 42-46.
18. Niemi, M. (2007) Role ofOATP transporters in the disposition of drugs. Pharmacogenomics, 8, 787-802.
19. Smith, N.F., Figg, W.D. and Sparreboom, A. (2005) Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opinion on Drug Metabolism and Toxicology, 1, 429-445.
20. Hagenbuch, B. and Meier, P.J. (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Archiv. European JournalofPhysiology, 447, 653-665.
21. Jacquemin, E., Hagenbuch, B., Stieger, B., Wolkoff, A.W. and Meier, P.J. (1994) Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proceedings of the National Academy of Sciencesofthe United StatesofAmerica, 91, 133-137.
22. Noe, B., Hagenbuch, B., Stieger, B. and Meier, P.J. (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proceedings ofthe National Academy of Sciences ofthe United States ofAmerica, 94, 10346-10350.
23. Cattori, V., Hagenbuch, B., Hagenbuch, N., Stieger, B., Ha, R., Winterhalter, K.E. and Meier, P.J. (2000) Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver. FEBS Letters, 474, 242-245.
24. Konig, J., Cui, Y., Nies, A.T. and Keppler, D. (2000) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. American Journal of Physiology. Gastrointestinal and Liver Physiology, 278, G156-G164.
25. Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.P. and Kirchgessner, T.G. (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. The Journal of Biological Chemistry, 274, 37161-37168.
26. Abe, T., Kakyo, M., Tokui, T., Nakagomi, R., Nishio, T., Nakai, D., Nomura, H., Unno, M., Suzuki, M., Naitoh, T., Matsuno, S. and Yawo, H. (1999) Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. The Journal of Biological Chemistry, 274, 17159-17163.
27. Konig, J., Cui, Y., Nies, A.T. and Keppler, D. (2000) Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. The Journal of Biological Chemistry, 275, 23161-23168.
28. Abe, T., Unno, M., Onogawa, T., Tokui, T., Kondo, T.N., Nakagomi, R., Adachi, H., Fujiwara, K., Okabe, M., Suzuki, T., Nunoki, K., Sato, E., Kakyo, M., Nishio, T., Sugita, J., Asano, N., Tanemoto, M., Seki, M., Date, F., Ono, K., Kondo, Y., Shiiba, K., Suzuki, M., Ohtani, H., Shimosegawa, T., Iinuma, K., Nagura, H., Ito, S. and Matsuno, S. (2001) LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology, 120 1689-1699.
29. Kullak-Ublick, G.A., Ismair, M.G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K., Meier, P.J. and Hagenbuch, B. (2001) Organic aniontransporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology, 120, 525-533.
30. Ismair, M.G., Stieger, B., Cattori, V., Hagenbuch, B., Fried, M., Meier, P.J. and Kullak-Ublick, G.A. (2001) Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology, 121, 1185-1190.
31. Yamashiro, W., Maeda, K., Hirouchi, M., Adachi, Y., Hu, Z. and Sugiyama, Y. (2006) Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 34, 1247-1254.
32. Ishiguro, N., Maeda, K., Kishimoto, W., Saito, A., Harada, A., Ebner, T., Roth, W., Igarashi, T. and Sugiyama, Y. (2006) Predominantcontributionof OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. DrugMetabolism and Disposition: The Biological Fate of Chemicals, 34, 1109-1115.
33. Yamada, A., Maeda, K., Kamiyama, E., Sugiyama, D., Kondo, T., Shiroyanagi, Y., Nakazawa, H., Okano, T., Adachi, M., Schuetz, J.D., Adachi, Y., Hu, Z., Kusuhara, H. and Sugiyama, Y. (2007) Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. DrugMetabolism and Disposition: The Biological Fate of Chemicals, 35, 2166-2176.
34. Nakagomi-Hagihara, R., Nakai, D., Kawai, K., Yoshigae, Y., Tokui, T., Abe, T. and Ikeda, T. (2006) OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 34, 862-869.
35. Cui, Y., Konig, J., Leier, I., Buchholz, U. and Keppler, D. (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. The Journal of Biological Chemistry, 276, 9626-9630.
36. Briz, O., Serrano, M.A., MacIas, R.I., Gonzalez-Gallego, J. and Marin, J.J. (2003) Role oforganic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. The Biochemical Journal, 371, 897-905.
37. Wang, P., Kim, R.B., Chowdhury, J.R. and Wolkoff, A.W. (2003) The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport. The Journal of Biological Chemistry, 278, 20695-20699.
38. van Montfoort, J.E., Hagenbuch, B., Fattinger, K.E., Muller, M., Groothuis, G.M., Meijer, D.K. and Meier, P.J. (1999) Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. The Journal ofPharmacology and Experimental Therapeutics, 291, 147-152.
39. Satoh, H., Yamashita, F., Tsujimoto, M., Murakami, H., Koyabu, N., Ohtani, H. and Sawada, Y. (2005) Citrus juices inhibit the function of human organic aniontransporting polypeptide OATP-B. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 33, 518-523.
40. Kobayashi, D., Nozawa, T., Imai, K., Nezu, J. , Tsuji, A. and Tamai, I. (2003) Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. The Journal ofPharmacology and Experimental Therapeutics, 306, 703-708.
41. Grube, M., Kock, K., Oswald, S., Draber, K. , Meissner, K., Eckel, L., Bohm, M., Felix, S.B., Vogelgesang, S., Jedlitschky, G., Siegmund, W., Warzok, R. and Kroemer, H.K. (2006) Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clinical Pharmacology and Therapeutics, 80, 607-620.
42. Hirano, M., Maeda, K., Shitara, Y. and Sugiyama, Y. (2006) Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 34, 1229-1236.
43. Mikkaichi, T., Suzuki, T., Tanemoto, M., Ito, S. and Abe, T. (2004) The organic anion transporter (OATP) family. Drug Metabolism and Pharmacokinetics, 19, 171-179.
44. Sun, W., Wu, R.R., van Poelje, P.D. and Erion, M.D. (2001) Isolation of a family of organic anion transporters from human liver and kidney. Biochemical and Biophysical Research Communications, 283, 417-422.
45. Rizwan, A.N. and Burckhardt, G. (2007) Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharmaceutical Research, 24, 450-470.
46. Kusuhara, H., Sekine, T., Utsunomiya-Tate, N., Tsuda, M., Kojima, R., Cha, S.H., Sugiyama, Y., Kanai, Y. and Endou, H. (1999) Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. The Journal of Biological Chemistry, 274, 13675-13680.
47. Cha, S.H., Sekine, T., Fukushima, J.I., Kanai, Y., Kobayashi, Y., Goya, T. and Endou, H. (2001) Identification and characterization of human organic anion transporter 3 expressing predominantly inthekidney. Molecular Pharmacology, 59, 1277-1286.
48. Sweet, D.H., Miller, D.S., Pritchard, J.B., Fujiwara, Y., Beier, D.R. and Nigam, S.K. (2002) Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. The Journal of Biological Chemistry, 277, 26934-26943.
49. Eraly, S.A. and Nigam, S.K. (2002) Novel human cDNAs homologous to Drosophila Orct and mammalian carnitine transporters. Biochemical and Biophysical Research Communications, 297, 1159-1166.
50. Shin, H.J., Anzai, N., Enomoto, A., He, X., Kimdo, K., Endou, H. and Kanai, Y. (2007) Novel liver-specific organic anion transporter OAT7 that operates the exchange of sulfate conjugates for short chain fatty acid butyrate. Hepatology (Baltimore, Md.), 45, 1046-1055.
51. Gorboulev, V., Ulzheimer, J.C., Akhoundova, A., Ulzheimer-Teuber, I., Karbach, U., Quester, S., Baumann, C., Lang, F., Busch, A.E. and Koepsell, H. (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA and Cell Biology, 16, 871-881.
52. Koepsell, H., Lips, K. and Volk, C. (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharmaceutical Research, 24, 1227-1251.
53. Jonker, J.W., Wagenaar, E., Mol, C.A., Buitelaar, M., Koepsell, H., Smit, J.W. and Schinkel, A.H. (2001) Reduced hepatic uptake and intestinal excretion oforganic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Molecular and Cellular Biology, 21, 5471-5477.
54. Grundemann, D., Liebich, G., Kiefer, N., Koster, S. and Schomig, E. (1999) Selective substrates for non-neuronal monoamine transporters. Molecular Pharmacology, 56, 1-10.
55. Nakamura, H., Sano, H., Yamazaki, M. and Sugiyama, Y. (1994) Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rathepatocytes: contribution of type I system. The Journal of Pharmacology and Experimental Therapeutics, 269, 1220-1227.
56. Wang, D.S., Jonker, J.W., Kato, Y., Kusuhara, H., Schinkel, A.H. and Sugiyama, Y. (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. The Journal of Pharmacology and Experimental Therapeutics, 302, 510-515.
57. Wang, D.S., Kusuhara, H., Kato, Y., Jonker, J.W., Schinkel, A.H. and Sugiyama, Y. (2003) Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Molecular Pharmacology, 63, 844-848.
58. Croop, J.M., Raymond, M., Haber, D., Devault, A., Arceci, R.J., Gros, P. and Housman, D.E. (1989) The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Molecular and Cellular Biology, 9, 1346-1350.
59. Gottesman, M.M. and Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annual Review of Biochemistry, 62, 385-427.
60. Schinkel, A.H. (1997) The physiological function of drug-transporting P-glycoproteins. Seminars in Cancer Biology, 8, 161-170.
61. Lin, J.H. and Yamazaki, M. (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clinical Pharmacokinetics, 42, 59-98.
62. Cvetkovic, M., Leake, B., Fromm, M.F., Wilkinson, G.R. and Kim, R.B. (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 27, 866-871.
63. Huang, L., Hoffman, T. and Vore, M. (1998) Adenosine triphosphate-dependent transport of estradiol-17beta (beta-D-glucuronide) in membrane vesicles by MDR1 expressed in insect cells. Hepatology (Baltimore, Md.), 28, 1371-1377.
64. Matsushima, S., Maeda, K., Kondo, C., Hirano, M., Sasaki, M., Suzuki, H. and Sugiyama, Y. (2005) Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic aniontransporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. The Journal ofPharmacology and Experimental Therapeutics, 314, 1059-1067.
65. Cordon-Cardo, C., O'Brien, J.P., Boccia, J., Casals, D., Bertino, J.R. and Melamed, M.R. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. The Journal ofHistochemistry and Cytochemistry, 38, 1277-1287.
66. Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P., et al. (1994) Disruptionofthe mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77, 491-502.
67. Schinkel, A.H., Mayer, U., Wagenaar, E., Mol, C.A., van Deemter, L., Smit, J.J., van der Valk, M.A., Voordouw, A.C., Spits, H., van Tellingen, O., Zijlmans, J.M., Fibbe, W.E. and Borst, P. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drugtransporting) P-glycoproteins. Proceedings ofthe National Academy of Sciences ofthe United States ofAmerica, 94, 4028-4033.
68. Smit, J.W., Schinkel, A.H., Weert, B. and Meijer, D.K. (1998) Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. British Journal ofPharmacology, 124, 416-424.
69. Kawahara, M., Sakata, A., Miyashita, T., Tamai, I. and Tsuji, A. (1999) Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. Journal of Pharmaceutical Sciences, 88, 1281-1287.
70. van Asperen, J., van Tellingen, O. and Beijnen, J.H. (2000) The role of mdrla P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. DrugMetaboHsmandDisposition: The Biological Fate of Chemicals, 28, 264-267.
71. Oude Elferink, R.P. and Paulusma, C.C. (2007) Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Archiv: European Journal of Physiology, 453, 601-610.
72. Buchler, M., Konig, J., Brom, M., Kartenbeck, J., Spring, H., Horie, T. and Keppler, D. (1996) cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. The Journal ofBiological Chemistry, 271, 15091-15098.
73. Ito, K., Suzuki, H., Hirohashi, T., Kume, K., Shimizu, T. and Sugiyama, Y. (1997) Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. The American Journal ofPhysiology, 272, G16-G22.
74. Nies, A.T. and Keppler, D. (2007) The apical conjugate efflux pump ABCC2 (MRP2). PflugersArchiv: European Journal ofPhysiology, 453, 643-659.
75. Shitara, Y. and Sugiyama, Y. (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacology & Therapeutics, 112, 71-105.
76. Herling, A.W., Schwab, D., Burger, H.J., Maas, J., Hammerl, R., Schmidt, D., Strohschein, S., Hemmerle, H., Schubert, G., Petry, S. and Kramer, W. (2002) Prolonged blood glucose reduction in mrp-2 deficient rats (GY/TR~) by the glucose-6-phosphate translocase inhibitor S 3025. Biochimica et Biophysica Acta, 1569, 105-110.
77. Fernandez-Checa, J.C., Takikawa, H., Horie, T., Ookhtens, M. and Kaplowitz, N. (1992) Canalicular transport of reduced glutathione in normal and mutant Eisai hyperbilirubinemic rats. The Journal ofBiological Chemistry, 267, 1667-1673.
78. Paulusma, C.C., van Geer, M.A., Evers, R., Heijn, M., Ottenhoff, R., Borst, P. and Oude Elferink, R.P. (1999) Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. The Biochemical Journal, 338 (Pt 2), 393-401.
79. Elferink, R.O. and Groen, A.K. (2002) Genetic defects in hepatobiliary transport. Biochimica et Biophysica Acta, 1586, 129-145.
80. Ishizuka, H., Konno, K., Shiina, T., Naganuma, H., Nishimura, K., Ito, K., Suzuki, H. and Sugiyama, Y. (1999) Species differences in the transport activity for organic anions across the bile canalicular membrane. The Journal of Pharmacology and Experimental Therapeutics, 290, 1324-1330.
81. Niinuma, K., Kato, Y., Suzuki, H., Tyson, C.A., Weizer, V., Dabbs, J.E., Froehlich, R., Green, C.E. and Sugiyama, Y. (1999) Primary active transport of organic anions on bile canalicular membrane in humans. The American Journal of Physiology, 276, G1153-G1164.
82. Ninomiya, M., Ito, K., Hiramatsu, R. and Horie, T. (2006) Functional analysis of mouse and monkey multidrug resistance-associated protein 2 (Mrp2). Drug Metabolism and Disposition: The Biological Fate of Chemicals, 34, 2056-2063.
83. Zimmermann, C., van de Wetering, K., van de Steeg, E., Wagenaar, E., Vens, C. and Schinkel, A.H. (2008) Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metabolism and Disposition: The Biological Fate of Chemicals, 36, 631-640.
84. Chu, X.Y., Strauss, J.R., Mariano, M.A., Li, J., Newton, D.J., Cai, X., Wang, R.W., Yabut, J., Hartley, D.P., Evans, D.C. and Evers, R. (2006) Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). TheJournal of Pharmacology and Experimental Therapeutics, 317, 579-589.
85. Zamek-Gliszczynski, M.J., Nezasa, K., Tian, X., Kalvass, J.C., Patel, N.J., Raub, T.J. and Brouwer, K.L. (2006) The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Molecular Pharmacology, 70, 2127-2133.
86. Takenaka, O., Horie, T., Kobayashi, K., Suzuki, H. and Sugiyama, Y. (1995) Kinetic analysis ofhepatobiliarytransport for conjugated metabolites in the perfused liver ofmutant rats (EHBR) with hereditary conjugated hyperbilirubinemia. Pharmaceutical Research, 12, 1746-1755.
87. Xiong, H., Turner, K.C., Ward, E.S., Jansen, P.L. and Brouwer, K.L. (2000) Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats. TheJournalofPharmacologyand Experimental Therapeutics, 295, 512-518.
88. Ogasawara, T. and Takikawa, H. (2001) Biliary excretion of phenolphthalein glucuronide in the rat. Hepatology Research, 20, 221-231.
89. Zamek-Gliszczynski, M.J., Hoffmaster, K.A., Humphreys, J.E., Tian, X., Nezasa, K. and Brouwer, K.L. (2006) Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. The Journal of Pharmacology and Experimental Therapeutics, 319, 459-467.
90. Tahara, H., Kusuhara, H., Fuse, E. and Sugiyama, Y. (2005) P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 33, 963-968.
91. Tian, X., Zamek-Gliszczynski, M.J., Li, J., Bridges, A.S., Nezasa, K., Patel, N.J., Raub, T.J. and Brouwer, K.L. (2008) Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 36, 61-64.
92. Matsushima, S., Maeda, K., Hayashi, H., Debori, Y., Schinkel, A.H., Schuetz, J.D., Kusuhara, H. and Sugiyama, Y. (2008) Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Molecular Pharmacology, 73, 1474-1483.
93. Vlaming, M.L., Mohrmann, K., Wagenaar, E., de Waart, D.R., Elferink, R.P., Lagas, J.S., van Tellingen, O., Vainchtein, L.D., Rosing, H., Beijnen, J. H., Schellens, J.H. and Schinkel, A.H. (2006) Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. The Journal of Pharmacology and Experimental Therapeutics, 318, 319-327.
94. Chu, X.Y., Kato, Y., Niinuma, K., Sudo, K. I., Hakusui, H. and Sugiyama, Y. (1997) Multispecific organic anion transporter is responsible for the biliary excretion ofthe camptothecin derivative irinotecan and its metabolites in rats. The Journal of Pharmacology and Experimental Therapeutics, 281, 304-314.
95. Mao, Q. and Unadkat, J.D. (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. The Aaps Journal, 7, E118-E133.
96. Robey, R.W., Polgar, O., Deeken, J., To, K.K.W. and Bates, S.E. (2007) Breast cancer resistance protein, in Drug Transporters (eds G. You and M.E. Morris), John Wiley & Sons, Inc., New Jersey, pp. 319-358.
97. Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H. and Sugiyama, Y. (2005) InvolvementofBCRP (ABCG2) in the biliary excretion of pitavastatin. Molecular Pharmacology, 68, 800-807.
98. Yamazaki, M., Kobayashi, K. and Sugiyama, Y. (1996) Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats. Biopharmaceutics & Drug Disposition, 17, 607-621.
99. Ando, T., Kusuhara, H., Merino, G., Alvarez, A.I., Schinkel, A.H. and Sugiyama, Y. (2007) Involvementofbreast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 35, 1873-1879.
100. Alrefai, W.A. and Gill, R.K. (2007) Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharmaceutical Research, 24, 1803-1823.
101. Stieger, B., Meier, Y. and Meier, P.J. (2007) The bile salt export pump. Pflugers Archiv: European Journal of Physiology, 453, 611-620.
102. Strautnieks, S.S., Bull, L.N., Knisely, A.S., Kocoshis, S.A., Dahl, N., Arnell, H., Sokal, E., Dahan, K., Childs, S., Ling, V., Tanner, M.S., Kagalwalla, A.F., Nemeth, A., Pawlowska, J., Baker, A., Mieli-Vergani, G. , Freimer, N.B., Gardiner, R.M. and Thompson, R.J. (1998) A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nature Genetics, 20, 233-238.
103. Hayashi, H., Takada, T., Suzuki, H., Akita, H. and Sugiyama, Y. (2005) Two common PFIC2 mutations are associated with the impaired membrane trafficking ofBSEP/ABCB11. Hepatology (Baltimore, Md.), 41, 916-924.
104. Hayashi, H. and Sugiyama, Y. (2007) 4-Phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology (Baltimore, Md.), 45, 1506-1516.
105. Fattinger, K., Funk, C., Pantze, M., Weber, C., Reichen, J., Stieger, B. and Meier, P.J. (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clinical Pharmacology and Therapeutics, 69, 223-231.
106. Lecureur, V., Sun, D., Hargrove, P., Schuetz, E.G., Kim, R.B., Lan, L.B. and Schuetz, J.D. (2000) Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Molecular Pharmacology, 57, 24-35.
107. Hirano, M., Maeda, K., Hayashi, H., Kusuhara, H. and Sugiyama, Y. (2005) Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. The Journal of Pharmacology and Experimental Therapeutics, 314, 876-882.
108. Omote, H., Hiasa, M., Matsumoto, T., Otsuka, M. and Moriyama, Y. (2006) The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends in Pharmacological Sciences, 27, 587-593.
109. Otsuka, M., Matsumoto, T., Morimoto, R., Arioka, S., Omote, H. and Moriyama, Y. (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proceedings of the National Academy of Sciences of the United States of America, 102, 17923-17928.
110. Masuda, S., Terada, T., Yonezawa, A., Tanihara, Y., Kishimoto, K., Katsura, T., Ogawa, O. and Inui, K. (2006) Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. Journal of the American Society of Nephrology, 17, 2127-2135.
111. Ohta, K.Y., Inoue, K., Hayashi, Y. and Yuasa, H. (2006) Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 34, 1868-1874.
112. Hiasa, M., Matsumoto, T., Komatsu, T. and Moriyama, Y. (2006) Wide variety of locations for rodent MATE1,atransporter protein that mediates the final excretion step for toxic organic cations. American Journal of Physiology. Cell Physiology, 291, C678-C686.
113. Hiasa, M., Matsumoto, T., Komatsu, T., Omote, H. and Moriyama, Y. (2007) Functional characterization of testis-specific rodent multidrug and toxic compound extrusion 2, a class III MATE-type polyspecific H+/organic cation exporter. American Journal of Physiology. Cell Physiology, 293, C1437-C1444.
114. Yokoo, S., Yonezawa, A., Masuda, S., Fukatsu, A., Katsura, T. and Inui, K. (2007) Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochemical Pharmacology, 74, 477-487.
115. Tanihara, Y., Masuda, S., Sato, T., Katsura, T., Ogawa, O. and Inui, K. (2007) Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochemical Pharmacology, 74, 359-371.
116. Chen, Y., Zhang, S., Sorani, M. and Giacomini, K.M. (2007) Transport of paraquat by human organic cation transporters and multidrug and toxic compoundextrusionfamily. TheJournalof Pharmacology and Experimental Therapeutics, 322, 695-700.
117. Hirohashi, T., Suzuki, H., Ito, K., Ogawa, K., Kume, K., Shimizu, T. and Sugiyama, Y. (1998) Hepatic expression ofmultidrug resistance-associated protein-like proteins maintained in Eisai hyperbilirubinemic rats. Molecular Pharmacology, 53, 1068-1075.
118. Konig, J., Rost, D., Cui, Y. and Keppler, D. (1999) Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology (Baltimore, Md.), 29, 1156-1163.
119. Scheffer, G.L., Kool, M., de Haas, M., de Vree, J.M., Pijnenborg, A.C., Bosman, D.K., Elferink, R.P., van der Valk, P., Borst, P. and Scheper, R.J. (2002) Tissue distribution and induction of human multidrug resistant protein 3. Laboratory Investigation; A Journal of Technical Methods and Pathology, 82, 193-201.
120. Zollner, G., Fickert, P., Silbert, D., Fuchsbichler, A., Marschall, H.U., Zatloukal, K., Denk, H. and Trauner, M. (2003) Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. Journal ofHepatology, 38, 717-727.
121. Zelcer, N., van de Wetering, K., de Waart, R., Scheffer, G.L., Marschall, H.U., Wielinga, P.R., Kuil, A., Kunne, C., Smith, A., van der Valk, M., Wijnholds, J., Elferink, R.O. and Borst, P. (2006) Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. Journal ofHepatology, 44, 768-775.
122. Belinsky, M.G., Bain, L.J., Balsara, B.B., Testa, J.R. and Kruh, G.D. (1998) Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily oftransporter proteins. Journal of the National Cancer Institute, 90, 1735-1741.
123. Kiuchi, Y., Suzuki, H., Hirohashi, T., Tyson, C.A. and Sugiyama, Y. (1998) cDNA cloning and inducible expression ofhuman multidrug resistance associated protein 3 (MRP3). FEBS Letters, 433, 149-152.
124. Belinsky, M.G., Dawson, P.A., Shchaveleva, I., Bain, L.J., Wang, R., Ling, V., Chen, Z.S., Grinberg, A., Westphal, H., Klein-Szanto, A., Lerro, A. and Kruh, G.D. (2005) Analysis of the in vivo functions of Mrp3. Molecular Pharmacology, 68, 160-168.
125. Zelcer, N., van de Wetering, K., Hillebrand, M., Sarton, E., Kuil, A., Wielinga, P.R., Tephly, T., Dahan, A., Beijnen, J.H. and Borst, P. (2005) Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proceedings of the National Academy of Sciences of the United States of America, 102, 7274-7279.
126. Zamek-Gliszczynski, M.J., Nezasa, K., Tian, X., Bridges, A.S., Lee, K., Belinsky, M.G., Kruh, G.D. and Brouwer, K.L. (2006) Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice. The Journal ofPharmacology and Experimental Therapeutics, 319, 1485-1491.
127. Tian, X., Swift, B., Zamek-Gliszczynski, M.J., Belinsky, M., Kruh, G. and Brouwer, K.L. (2008) Impact ofbasolateral Mrp3 (Abcc3) and Mrp4 (Abcc4) on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 36, 911-915.
128. Rius, M., Nies, A.T., Hummel-Eisenbeiss, J. , Jedlitschky, G. and Keppler, D. (2003) Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology (Baltimore, Md.), 38, 374-384.
129. Chen, C. and Klaassen, C.D. (2004) Rat multidrug resistance protein 4 (Mrp4, Abcc4): molecular cloning, organ distribution, postnatal renal expression, and chemical inducibility. Biochemical and Biophysical Research Communications, 317, 46-53.
130. Leggas, M., Adachi, M., Scheffer, G.L., Sun, D., Wielinga, P., Du, G., Mercer, K. E., Zhuang, Y., Panetta, J.C., Johnston, B., Scheper, R.J., Stewart, C.F. and Schuetz, J.D. (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Molecular and Cellular Biology, 24, 7612-7621.
131. Nies, A.T., Jedlitschky, G., Konig, J., Herold-Mende, C., Steiner, H.H., Schmitt, H.P. and Keppler, D. (2004) Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), inhumanbrain. Neuroscience, 129, 349-360.
132. Smeets, P.H., van Aubel, R.A., van Wouterse, A.C., den Heuvel, J.J. and Russel, F.G. (2004) Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. Journal ofthe American Society of Nephrology, 15, 2828-2835.
133. van Aubel, R.A., Smeets, P.H., Peters, J.G., Bindels, R.J. and Russel, F.G. (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative effluxpump forurinary cAMP and cGMP. Journal ofthe American Society of Nephrology, 13 595-603.
134. Rius, M., Thon, W.F., Keppler, D. and Nies, A.T. (2005) Prostanoid transport by multidrug resistance protein 4 (MRP4/ABCC4) localized in tissues ofthe human urogenital tract. The Journal of Urology, 174, 2409-2414.
135. Mennone, A., Soroka, C.J., Cai, S.Y., Harry, K., Adachi, M., Hagey, L., Schuetz, J.D. and Boyer, J.L. (2006) Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology (Baltimore, Md.), 43, 1013-1021.
136. Denk, G.U., Soroka, C.J., Takeyama, Y., Chen, W.S., Schuetz, J.D. and Boyer, J.L. (2004) Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. Journal of Hepatology, 40, 585-591.
137. Borst, P., Evers, R., Kool, M. and Wijnholds, J. (1999) The multidrug resistance protein family. Biochimica et Biophysica Acta, 1461, 347-357.
138. Ros, J.E., Libbrecht, L., Geuken, M., Jansen, P.L. and Roskams, T.A. (2003) High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. The Journal of Pathology, 200, 553-560.
139. Donner, M.G., Warskulat, U., Saha, N. and Haussinger, D. (2004) Enhanced expression ofbasolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS. Biological Chemistry, 385, 331-339.
140. Belinsky, M.G., Chen, Z.S., Shchaveleva, I., Zeng, H. and Kruh, G.D. (2002) Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Research, 62, 6172-6177.
141. Ilias, A., Urban, Z., Seidl, T.L., Le Saux, O., Sinko, E., Boyd, C.D., Sarkadi, B. and Varadi, A. (2002) Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). The Journal ofBiological Chemistry, 277, 16860-16867.
142. Bergen, A.A., Plomp, A.S., Schuurman, E. J., Terry, S., Breuning, M., Dauwerse, H., Swart, J., Kool, M., van Soest, S., Baas, F. , ten Brink, J.B. and de Jong, P.T. (2000) Mutations in ABCC6 cause pseudoxanthoma elasticum. Nature Genetics, 25, 228-231.
143. Le Saux, O., Urban, Z., Tschuch, C., Csiszar, K., Bacchelli, B., Quaglino, D., Pasquali-Ronchetti, I., Pope, F.M., Richards, A., Terry, S., Bercovitch, L., de Paepe, A. and Boyd, C.D. (2000) Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nature Genetics, 25, 223-227.
144. Ringpfeil, F., Lebwohl, M.G., Christiano, A.M. and Uitto, J. (2000) Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proceedings of the National Academy ofSciences ofthe United States of America, 97, 6001-6006.
145. Landrier, J.F., Eloranta, J.J., Vavricka, S.R. and Kullak-Ublick, G.A. (2006) The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. American Journal of Physiology. Gastrointestinal and Liver Physiology, 290, G476-G485.
146. Lee, H., Zhang, Y., Lee, F.Y., Nelson, S.F., Gonzalez, F.J. and Edwards, P.A. (2006) FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. Journal of Lipid Research, 47, 201-214.
147. Boyer, J.L., Trauner, M., Mennone, A., Soroka, C.J., Cai, S.Y., Moustafa, T., Zollner, G., Lee, J.Y. and Ballatori, N. (2006) Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. American Journal of Physiology. Gastrointestinal and Liver Physiology, 290, G1124-G1130.
148. Mahagita, C., Grassl, S.M., Piyachaturawat, P. and Ballatori, N. (2007) Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. American Journal of Physiology. Gastrointestinal and Liver Physiology, 293, G271-G278.
149. Li, L., Meier, P.J. and Ballatori, N. (2000) Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Molecular Pharmacology, 58, 335-340.
150. Shitara, Y., Li, A.P., Kato, Y., Lu, C., Ito, K., Itoh, T. and Sugiyama, Y. (2003) Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes. Drug Metabolism and Pharmacokinetics, 18, 33-41.
151. Hirano, M., Maeda, K., Shitara, Y. and Sugiyama, Y. (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. The Journal of Pharmacology and Experimental Therapeutics, 311, 139-146.
152. Jigorel, E., Le Vee, M., Boursier-Neyret, C., Bertrand, M. and Fardel, O. (2005) Functional expression of sinusoidal drug transporters in primary human and rat hepatocytes. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 33, 1418-1422.
153. Ishigami, M., Tokui, T., Komai, T., Tsukahara, K., Yamazaki, M. and Sugiyama, Y. (1995) Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes. Pharmaceutical Research, 12, 1741-1745.
154. Rippin, S.J., Hagenbuch, B., Meier, P.J. and Stieger, B. (2001) Cholestatic expression pattern of sinusoidal and canalicular organic anion transport systems in primary cultured rat hepatocytes. Hepatology (Baltimore, Md.), 33, 776-782.
155. Miyauchi, S., Sawada, Y., Iga, T., Hanano, M. and Sugiyama, Y. (1993) Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers. Pharmaceutical Research, 10, 434-440.
156. Kato, Y., Akhteruzzaman, S., Hisaka, A. and Sugiyama, Y. (1999) Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats. The Journal of Pharmacology and Experimental Therapeutics, 288, 568-574.
157. Kouzuki, H., Suzuki, H., Ito, K., Ohashi, R. and Sugiyama, Y. (1998) Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. The Journal ofPharmacology and Experimental Therapeutics, 286, 1043-1050.
158. Kouzuki, H., Suzuki, H., Ito, K., Ohashi, R. and Sugiyama, Y. (1999) Contribution oforganic anion transporting polypeptide to uptake ofits possible substrates into rat hepatocytes. The Journal ofPharmacology and Experimental Therapeutics, 288, 627-634.
159. Crespi, C.L.and Penman, B.W. (1997) Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Advances in Pharmacology (San Diego, Calif.), 43, 171-188.
160. Sekine, T., Cha, S.H., Tsuda, M., Apiwattanakul, N., Nakajima, N., Kanai, Y. and Endou, H. (1998) Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Letters, 429, 179-182.
161. Shimizu, M., Fuse, K., Okudaira, K., Nishigaki, R., Maeda, K., Kusuhara, H. and Sugiyama, Y. (2005) Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 33, 1477-1481.
162. Hagenbuch, B., Scharschmidt, B.F. and Meier, P.J. (1996) Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes. The Biochemical Journal, 316 (Pt 3), 901-904.
163. Nakai, D., Nakagomi, R., Furuta, Y., Tokui, T., Abe, T., Ikeda, T. and Nishimura, K. (2001) Human liver-specific organic aniontransporter, LST-1, mediates uptake ofpravastatin by human hepatocytes. The Journal ofPharmacology and Experimental Therapeutics, 297, 861-867.
164. Materna, V., Stege, A., Surowiak, P., Priebsch, A. and Lage, H. (2006) RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochemical and Biophysical Research Communications, 348, 153-157.
165. Nieth, C., Priebsch, A., Stege, A. and Lage, H. (2003) Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Letters, 545, 144-150.
166. Aoki, J., Suzuki, H. and Sugiyama, Y. (2000) Quantitative prediction of in vivo biliary excretion clearance across the bile canalicular membrane from in vitro transport studies with isolated membrane vesicles. Millennial World Congress of Pharmaceutical Sciences, April 16-20, San Francisco, p. 92.
167. Allen, J.D., van Loevezijn, A., Lakhai, J.M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J.H., Koomen, G.J. and Schinkel, A.H. (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Molecular Cancer Therapeutics, 1, 417-425.
168. Dantzig, A.H., Shepard, R.L., Cao, J., Law, K.L., Ehlhardt, W.J., Baughman, T.M., Bumol, T.F. and Starling, J.J. (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Research, 56, 4171-4179.
169. Kusunoki, N., Takara, K., Tanigawara, Y., Yamauchi, A., Ueda, K., Komada, F., Ku, Y., Kuroda, Y., Saitoh, Y. and Okumura, K. (1998) Inhibitory effects of a cyclosporin derivative, SDZ PSC, 833, ontransport of doxorubicin and vinblastine via human P-glycoprotein. Japanese Journal of Cancer Research: Gann., 89, 1220-1228.
170. LeCluyse, E.L., Audus, K.L. and Hochman, J.H. (1994) Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. The American Journal of Physiology, 266, C1764-C1774.
171. Liu, X., LeCluyse, E.L., Brouwer, K.R., Lightfoot, R.M., Lee, J.I. and Brouwer, K.L. (1999) Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. The Journal of Pharmacology and Experimental Therapeutics, 289, 1592-1599.
172. Hoffmaster, K.A., Turncliff, R.Z., LeCluyse, E.L., Kim, R.B., Meier, P.J. and Brouwer, K.L. (2004) P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharmaceutical Research, 21, 1294-1302.
173. Liu, X., Chism, J.P., LeCluyse, E.L., Brouwer, K.R. and Brouwer, K.L. (1999) Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 27, 637-644.
174. Bi, Y.A., Kazolias, D. and Duignan, D.B. (2006) Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 34, 1658-1665.
175. Ghibellini, G., Vasist, L.S., Leslie, E.M., Heizer, W.D., Kowalsky, R.J., Calvo, B.F. and Brouwer, K.L. (2007) In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clinical Pharmacology and Therapeutics, 81, 406-413.
176. Cui, Y., Konig, J. and Keppler, D. (2001) Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Molecular Pharmacology, 60, 934-943.
177. Sasaki, M., Suzuki, H., Ito, K., Abe, T. and Sugiyama, Y. (2002) Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). The Journal ofBiological Chemistry, 277, 6497-6503.
178. Sasaki, M., Suzuki, H., Aoki, J., Ito, K., Meier, P.J. and Sugiyama, Y. (2004) Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Molecular Pharmacology, 66, 450-459.
179. Ishiguro, N., Maeda, K., Saito, A., Kishimoto, W., Matsushima, S., Ebner, T., Roth, W., Igarashi, T. and Sugiyama, Y. (2008) Establishment of a set of double transfectants co-expressing organic anion transporting polypeptide 1B3 (OATP1B3) and hepatic efflux transporters for the characterization of the hepatobiliary transport oftelmisartan acylglucuronide. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 36, 796-805.
180. Mita, S., Suzuki, H., Akita, H., Stieger, B., Meier, P.J., Hofmann, A.F. and Sugiyama, Y. (2005) Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump. American Journal of Physiology. Gastrointestinal and Liver Physiology, 288, G159-G167.
181. Kopplow, K., Letschert, K., Konig, J., Walter, B. and Keppler, D. (2005) Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Molecular Pharmacology, 68, 1031-1038.
182. Nies, A.T., Herrmann, E., Brom, M. and Keppler, D. (2008) Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn-Schmiedeberg s Archives of Pharmacology, 376, 449-461.
183. Kerb, R. (2006) Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Letters, 234, 4-33.
184. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H.P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. and Brinkmann, U. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings ofthe National Academy of Sciences of the United States of America, 97, 3473-3478.
185. Pauli-Magnus, C. and Kroetz, D.L. (2004) Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharmaceutical Research, 21, 904-913.
186. Konig, J., Seithel, A., Gradhand, U. and Fromm, M.F. (2006) Pharmacogenomics of human OATP transporters. Naunyn-Schmiedeberg s Archives of Pharmacology, 372, 432-443.
187. Nishizato, Y., Ieiri, I., Suzuki, H., Kimura, M., Kawabata, K., Hirota, T., Takane, H., Irie, S., Kusuhara, H., Urasaki, Y., Urae, A., Higuchi, S., Otsubo, K. and Sugiyama, Y. (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clinical Pharmacology and Therapeutics, 73, 554-565.
188. Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M. and Chiba, K. (2005) Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G,by using transient expression systems ofHeLa and HEK293 cells. Pharmacogenetics and Genomics, 15, 513-522.
189. Iwai, M., Suzuki, H., Ieiri, I., Otsubo, K. and Sugiyama, Y. (2004) Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics, 14, 749-757.
190. Maeda, K., Ieiri, I., Yasuda, K., Fujino, A., Fujiwara, H., Otsubo, K., Hirano, M., Watanabe, T., Kitamura, Y., Kusuhara, H. and Sugiyama, Y. (2006) Effects oforganic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clinical Pharmacology and Therapeutics, 79, 427-439.
191. Niemi, M., Neuvonen, P.J., Hofmann, U., Backman, J.T., Schwab, M., Lutjohann, D., von Bergmann, K., Eichelbaum, M. and Kivisto, K.T. (2005) Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype 7. Pharmacogenetics and Genomics, 15, 303-309.
192. Niemi, M., Backman, J.T., Kajosaari, L.I., Leathart, J.B., Neuvonen, M., Daly, A.K., Eichelbaum, M., Kivisto, K.T. and Neuvonen, P.J. (2005) Polymorphic organic anion transporting polypeptide 1B1isa major determinant of repaglinide pharmacokinetics. Clinical Pharmacology and Therapeutics, 77, 468-478.
193. Han, J.Y., Lim, H.S., Shin, E.S., Yoo, Y.K., Park, Y.H., Lee, J.E., Kim, H.T. and Lee, J.S. (2008) Influence of the organic aniontransporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 59, 69-75.
194. Tsujimoto, M., Hirata, S., Dan, Y., Ohtani, H. and Sawada, Y. (2006) Polymorphisms and linkage disequilibrium ofthe OATP8 (OATP1B3) gene in Japanese subjects. Drug Metabolism and Pharmacokinetics, 21, 165-169.
195. Smith, N.F., Marsh, S., Scott-Horton, T.J., Hamada, A., Mielke, S., Mross, K., Figg, W.D., Verweij, J., McLeod, H.L. and Sparreboom, A. (2007) Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clinical Pharmacology and Therapeutics, 81, 76-82.
196. Yamasaki, Y., Ieiri, I., Kusuhara, H., Sasaki, T., Kimura, M., Tabuchi, H., Ando, Y., Irie, S., Ware, J., Nakai, Y., Higuchi, S. and Sugiyama, Y. (2008) Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 BCRP) gene polymorphisms in humans. Clinical Pharmacology and Therapeutics 84, 95-103.
197. Zhang, W., Yu, B.N., He, Y.J., Fan, L., Li, Q., Liu, Z.Q., Wang, A., Liu, Y.L., Tan, Z. R., Fen, J., Huang, Y.F. and Zhou, H.H. (2006) Role ofBCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clinica Chimica Acta; International Journal of Clinical Chemistry, 373, 99-103.
198. Sparreboom, A., Gelderblom, H., Marsh, S., Ahluwalia, R., Obach, R., Principe, P., Twelves, C., Verweij, J. and McLeod, H.L. (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clinical Pharmacology and Therapeutics, 76, 38-44.
199. Kondo, C., Suzuki, H., Itoda, M., Ozawa, S., Sawada, J., Kobayashi, D., Ieiri, I., Mine, K., Ohtsubo, K. and Sugiyama, Y. (2004) Functional analysis of SNPs variants ofBCRP/ABCG2. Pharmaceutical Research, 21, 1895-1903.
200. Kobayashi, D., Ieiri, I., Hirota, T., Takane, H., Maegawa, S., Kigawa, J., Suzuki, H., Nanba, E., Oshimura, M., Terakawa, N., Otsubo, K., Mine, K. and Sugiyama, Y. (2005) Functional assessment ofABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 33, 94-101.
201. Choi, J.H., Ahn, B.M., Yi, J., Lee, J.H., Nam, S.W., Chon, C.Y, Han, K.H., Ahn, S.H., Jang, I.J., Cho, J.Y., Suh, Y., Cho, M.O., Lee, J.E., Kim, K.H. and Lee, M.G. (2007) MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenetics and Genomics, 17, 403-415.
202. Daly, A.K., Aithal, G.P., Leathart, J.B., Swainsbury, R.A., Dang, T.S. and Day, C. P. (2007) Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology, 132, 272-281.
203. de Jong, F.A., Scott-Horton, T.J., Kroetz, D. L., McLeod, H.L., Friberg, L.E., Mathijssen, R.H., Verweij, J., Marsh, S. and Sparreboom, A. (2007) Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clinical Pharmacology and Therapeutics, 81, 42-49.
204. Shu, Y., Sheardown, S.A., Brown, C., Owen, R.P., Zhang, S., Castro, R.A., Ianculescu, A.G., Yue, L., Lo, J.C., Burchard, E.G., Brett, C.M. and Giacomini, K.M. (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. The Journal of Clinical Investigation, 117, 1422-1431.
205. Shu, Y., Brown, C., Castro, R.A., Shi, R.J., Lin, E.T., Owen, R.P., Sheardown, S.A., Yue, L., Burchard, E.G., Brett, C.M. and Giacomini, K.M. (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clinical Pharmacology and Therapeutics, 83, 273-280.
206. Vavricka, S.R., Van Montfoort, J., Ha, H.R., Meier, P.J. and Fattinger, K. (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology (Baltimore, Md.), 36, 164-172.
207. Backman, J.T., Kyrklund, C., Neuvonen, M. and Neuvonen, P.J. (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clinical Pharmacology and Therapeutics, 72, 685-691.
208. Muck, W., Mai, I., Fritsche, L., Ochmann, K., Rohde, G., Unger, S., Johne, A., Bauer, S., Budde, K., Roots, I., Neumayer, H.H. and Kuhlmann, J. (1999) Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clinical Pharmacology and Therapeutics, 65, 251-261.
209. Shitara, Y., Itoh, T., Sato, H., Li, A.P. and Sugiyama, Y. (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. The Journal of Pharmacology and Experimental Therapeutics, 304, 610-616.
210. Regazzi, M.B., Iacona, I., Campana, C., Raddato, V., Lesi, C., Perani, G., Gavazzi, A. and Vigano, M. (1993) Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplantation Proceedings, 25, 2732-2734.
211. Simonson, S.G., Raza, A., Martin, P.D., Mitchell, P.D., Jarcho, J.A., Brown, C.D., Windass, A.S. and Schneck, D.W. (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clinical Pharmacology and Therapeutics, 76, 167-177.
212. Hasunuma, T., Nakamura, M., Yachi, T., Arisawa, N., Fukushima, K. and Iijima, H. (2003) The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. Journal of Clinical Therapy Medicine, 19, 381-389.
213. Kajosaari, L.I., Niemi, M., Neuvonen, M., Laitila, J., Neuvonen, P.J. and Backman, J.T. (2005) Cyclosporine markedly raises the plasma concentrations ofrepaglinide. Clinical Pharmacology and Therapeutics, 78, 388-399.
214. Treiber, A., Schneiter, R., Delahaye, S. and Clozel, M. (2004) Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. The Journal of Pharmacology and Experimental Therapeutics, 308, 1121-1129.
215. Shitara, Y., Hirano, M., Sato, H. and Sugiyama, Y. (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. The Journal ofPharmacology and Experimental Therapeutics, 311, 228-236.
216. Kyrklund, C., Backman, J.T., Neuvonen, M. and Neuvonen, P.J. (2003) Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clinical Pharmacology and Therapeutics, 73, 538-544.
217. Mathew, P., Cuddy, T. and Tracewell, W.G. (2004) An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers (abstract PI-115). Clinical Pharmacology and Therapeutics, 75, 33.
218. Schneck, D.W., Birmingham, B.K., Zalikowski, J.A., Mitchell, P.D., Wang, Y., Martin, P.D., Lasseter, K.C., Brown, C.D., Windass, A.S. and Raza, A. (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clinical Pharmacology and Therapeutics, 75, 455-463.
219. Treiber, A., Schneiter, R., Hausler, S. and Stieger, B. (2007) Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 35, 1400-1407.
220. Lau, Y.Y., Okochi, H., Huang, Y. and Benet, L.Z. (2006) Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. The Journal of Pharmacology and Experimental Therapeutics, 316, 762-771.
221. Asberg, A., Hartmann, A., Fjeldsa, E., Bergan, S. and Holdaas, H. (2001) Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. American Journal ofTransplantation, 1, 382-386.
222. Ichimaru, N., Takahara, S., Kokado, Y., Wang, J.D., Hatori, M., Kameoka, H., Inoue, T. and Okuyama, A. (2001) Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis, 158, 417-423.
223. Mazzu, A.L., Lasseter, K.C., Shamblen, E.C., Agarwal, V., Lettieri, J. and Sundaresen, P. (2000) Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clinical Pharmacology and Therapeutics, 68, 391-400.
224. Neuvonen, P.J., Kantola, T. and Kivisto, K.T. (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clinical Pharmacology and Therapeutics, 63, 332-341.
225. Campbell, S.D., de Morais, S.M. and Xu, J.J. (2004) Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chemico-Biological Interactions, 150, 179-187.
226. Kobayashi, Y., Sakai, R., Ohshiro, N., Ohbayashi, M., Kohyama, N. and Yamamoto, T. (2005) Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 33, 619-622.
227. Jonkman, J.H. and Upton, R.A. (1984) Pharmacokinetic drug interactions with theophylline. Clinical Pharmacokinetics, 9, 309-334.
228. Fichtenbaum, C.J., Gerber, J.G., Rosenkranz, S.L., Segal, Y., Aberg, J.A., Blaschke, T., Alston, B., Fang, F., Kosel, B. and Aweeka, F. (2002) Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS (London, England), 16, 569-577.
229. Gerber, J.G., Rosenkranz, S.L., Fichtenbaum, C.J., Vega, J.M., Yang, A., Alston, B.L., Brobst, S.W., Segal, Y. and Aberg, J.A. (2005) Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. Journal of Acquired Immune Deficiency Syndromes, 39, 307-312.
230. Kyrklund, C., Backman, J.T., Neuvonen, M. and Neuvonen, P.J. (2004) Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology, 57, 181-187.
231. Bohan, A. and Boyer, J.L. (2002) Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Seminars in Liver Disease, 22, 123-136.
232. Funk, C., Ponelle, C., Scheuermann, G. and Pantze, M. (2001) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Molecular Pharmacology, 59, 627-635.
233. Funk, C., Pantze, M., Jehle, L., Ponelle, C., Scheuermann, G., Lazendic, M. and Gasser, R. (2001) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology, 167, 83-98.
234. Kostrubsky, V.E., Strom, S.C., Hanson, J., Urda, E., Rose, K., Burliegh, J., Zocharski, P., Cai, H., Sinclair, J.F. and Sahi, J. (2003) Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicological Sciences, 76, 220-228.
235. Mita, S., Suzuki, H., Akita, H., Hayashi, H., Onuki, R., Hofmann, A.F. and Sugiyama, Y. (2006) Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 34, 1575-1581.
236. Akita, H., Suzuki, H., Ito, K., Kinoshita, S., Sato, N., Takikawa, H. and Sugiyama, Y. (2001) Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochimica et Biophysica Acta, 1511, 7-16.
237. Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G.A. and Meier, P.J. (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology, 118, 422-430.
238. Huang, L., Smit, J.W., Meijer, D.K. and Vore, M. (2000) Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. Hepatology (Baltimore, Md.), 32, 66-72.
239. Chu, X.Y., Kato, Y. and Sugiyama, Y. (1997) Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites inrats. CancerResearch, 57, 1934-1938.
240. Chu, X.Y., Kato, Y., Ueda, K., Suzuki, H., Niinuma, K., Tyson, C.A., Weizer, V., Dabbs, J.E., Froehlich, R., Green, C.E. and Sugiyama, Y. (1998) Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Research, 58, 5137-5143.
241. Horikawa, M., Kato, Y. and Sugiyama, Y. (2002) Reduced gastrointestinal toxicity following inhibition of the biliary excretion ofirinotecan and its metabolites by probenecid in rats. Pharmaceutical Research, 19, 1345-1353.
242. Angelin, B., Arvidsson, A., Dahlqvist, R., Hedman, A. and Schenck-Gustafsson, K. (1987) Quinidine reduces biliary clearance of digoxin in man. European Journal of Clinical Investigation, 17, 262-265.
243. Adachi, Y., Suzuki, H. and Sugiyama, Y. (2001) Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharmaceutical Research, 18, 1660-1668.
244. Shitara, Y., Sato, H. and Sugiyama, Y. (2005) Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annual Review of Pharmacology and Toxicology, 45, 689-723.
245. Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H. and Sugiyama, Y. (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacological Reviews, 50, 387-412.
246. Ueda, K., Kato, Y., Komatsu, K. and Sugiyama, Y. (2001) Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. The Journal of Pharmacology and Experimental Therapeutics, 297, 1036-1043.
247. Takano, A., Kusuhara, H., Suhara, T., Ieiri, I. , Morimoto, T., Lee, Y.J., Maeda, J., Ikoma, Y., Ito, H., Suzuki, K. and Sugiyama, Y. (2006) Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. Journal ofNuclear Medicine, 47, 1427-1433.
248. Sasongko, L., Link, J.M., Muzi, M., Mankoff, D.A., Yang, X., Collier, A.C., Shoner, S.C. and Unadkat, J.D. (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clinical Pharmacology and Therapeutics 77, 503-514.
249. Fuhr, U., Jetter, A. and Kirchheiner, J. (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clinical Pharmacology and Therapeutics, 81, 270-283.
250. Maeda, K. and Sugiyama, Y. (2007) In vitro-in vivo scale-up of drug transport activities, in Drug Transporters (eds G. You and M.E. Morris), John Wiley & Sons, Inc., New Jersey, pp. 557-588.
251. Tamai, I., Nozawa, T., Koshida, M., Nezu, J. , Sai, Y. and Tsuji, A. (2001) Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharmaceutical Research, 18, 1262-1269.
252. Tamai, I., Nezu, J., Uchino, H., Sai, Y., Oku, A., Shimane, M. and Tsuji, A. (2000) Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochemical and Biophysical Research Communications, 273, 251-260.
253. Noe, J., Portmann, R., Brun, M.E. and Funk, C. (2007) Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 35, 1308-1314.
254. Sandhu, P., Lee, W., Xu, X., Leake, B.F., Yamazaki, M., Stone, J.A., Lin, J.H., Pearson, P.G. and Kim, R.B. (2005) Hepatic uptake of the novel antifungal agent caspofungin. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 33, 676-682.
255. Meier-Abt, F., Faulstich, H. and Hagenbuch, B. (2004) Identification of phalloidin uptake systems of rat and human liver. Biochimica et Biophysica Acta, 1664, 64-69.
256. Nozawa, T., Sugiura, S., Nakajima, M., Goto, A., Yokoi, T., Nezu, J., Tsuji, A. and Tamai, I. (2004) Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 32, 291-294.
257. Tirona, R.G., Leake, B.F., Wolkoff, A.W. and Kim, R.B. (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. The Journal of Pharmacology and Experimental Therapeutics, 304, 223-228.
258. Lu, W.J., Tamai, I., Nezu, J., Lai, M.L. and Huang, J.D. (2006) Organic anion transporting polypeptide-C mediates arsenicuptake inHEK-293 cells. Journalof Biomedical Science, 13, 525-533.
259. Katz, D.A., Carr, R., Grimm, D.R., Xiong, H., Holley-Shanks, R., Mueller, T., Leake, B., Wang, Q., Han, L., Wang, P.G., Edeki, T., Sahelijo, L., Doan, T., Allen, A., Spear, B.B. and Kim, R.B. (2006) Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clinical Pharmacology and Therapeutics, 79, 186-196.
260. Liu, L., Cui, Y., Chung, A.Y., Shitara, Y., Sugiyama, Y., Keppler, D. and Pang, K.S. (2006) Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. The Journal ofPharmacology and Experimental Therapeutics, 318, 395-402.
261. Nozawa, T., Tamai, I., Sai, Y., Nezu, J. and Tsuji, A. (2003) Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. The Journal of Pharmacy and Pharmacology, 55, 1013-1020.
262. Fischer, W.J., Altheimer, S., Cattori, V., Meier, P.J., Dietrich, D.R. and Hagenbuch, B. (2005) Organic anion transporting polypeptides expressed in liver and brain mediate uptake of microcystin. Toxicology and Applied Pharmacology, 203, 257-263.
263. Nozawa, T., Minami, H., Sugiura, S., Tsuji, A. and Tamai, I. (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 33, 434-439.
264. Smith, N.F., Acharya, M.R., Desai, N., Figg, W.D. and Sparreboom, A. (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biology & Therapy, 4, 815-818.
265. Briz, O., Serrano, M.A., Rebollo, N., Hagenbuch, B., Meier, P.J., Koepsell, H. and Marin, J.J. (2002) Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum (II) toward liver cells. Molecular Pharmacology, 61, 853-860.
266. Tsuda-Tsukimoto, M., Maeda, T., Iwanaga, T., Kume, T. and Tamai, I. (2006) Characterization of hepatobiliary transport systems ofa novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Pharmaceutical Research, 23, 2646-2656.
267. Yamaguchi, H., Okada, M., Akitaya, S., Ohara, H., Mikkaichi, T., Ishikawa, H., Sato, M., Matsuura, M., Saga, T., Unno, M., Abe, T., Mano, N., Hishinuma, T. and Goto, J. (2006) Transport of fluorescent chenodeoxycholic acid via the human organic aniontransporters OATP1B1 and OATP1B3. Journal of Lipid Research, 47, 1196-1202.
268. Mwinyi, J., Johne, A., Bauer, S., Roots, I. and Gerloff, T. (2004) Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clinical Pharmacology and Therapeutics, 75, 415-421.
269. Niemi, M., Schaeffeler, E., Lang, T., Fromm, M.F., Neuvonen, M., Kyrklund, C., Backman, J.T., Kerb, R., Schwab, M., Neuvonen, P.J., Eichelbaum, M. and Kivisto, K.T. (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics, 14, 429-440.
270. Niemi, M., Arnold, K.A., Backman, J.T., Pasanen, M.K., Godtel-Armbrust, U., Wojnowski, L., Zanger, U.M., Neuvonen, P.J., Eichelbaum, M., Kivisto, K.T. and Lang, T. (2006) Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenetics and Genomics, 16, 801-808.
271. Ho, R.H., Choi, L., Lee, W., Mayo, G., Schwarz, U.I., Tirona, R.G., Bailey, D.G., Michael Stein, C. and Kim, R.B. (2007) Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenetics and Genomics, 17, 647-656.
272. Igel, M., Arnold, K.A., Niemi, M., Hofmann, U., Schwab, M., Lutjohann, D., von Bergmann, K., Eichelbaum, M. and Kivisto, K.T. (2006) Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clinical Pharmacology and Therapeutics, 79, 419-426.
273. Chung, J.Y., Cho, J.Y., Yu, K.S., Kim, J.R., Oh, D.S., Jung, H.R., Lim, K.S., Moon, K.H., Shin, S.G. and Jang, I.J. (2005) EffectofOATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clinical Pharmacology and Therapeutics, 78, 342-350.
274. Ieiri, I., Suwannakul, S., Maeda, K., Uchimaru, H., Hashimoto, K., Kimura, M., Fujino, H., Hirano, M., Kusuhara, H., Irie, S., Higuchi, S. and Sugiyama, Y. (2007) SLCO1B1 (OATP1B1, an uptake transporter) andABCG2 (BCRP, anefflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clinical Pharmacology and Therapeutics, 82, 541-547.
275. Lee, E., Ryan, S., Birmingham, B., Zalikowski, J., March, R., Ambrose, H., Moore, R., Lee, C., Chen, Y. and Schneck, D. (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clinical Pharmacology and Therapeutics, 78, 330-341.
276. Choi, J.H., Lee, M.G., Cho, J.Y., Lee, J.E., Kim, K.H. and Park, K. (2008) Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clinical Pharmacology and Therapeutics, 83, 251-257.
277. Pasanen, M.K., Fredrikson, H., Neuvonen, P.J. and Niemi, M. (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clinical Pharmacology and Therapeutics, 82, 726-733.
278. Pasanen, M.K., Neuvonen, M., Neuvonen, P.J. and Niemi, M. (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and Genomics, 16, 873-879.
279. Niemi, M., Pasanen, M.K. and Neuvonen, P.J. (2006) SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clinical Pharmacology and Therapeutics, 80, 356-366.
280. Zhang, W., He, Y.J., Han, C.T., Liu, Z.Q., Li, Q., Fan, L., Tan, Z.R., Zhang, W.X., Yu, B.N., Wang, D., Hu, D.L. and Zhou, H.H. (2006) Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. British Journal of Clinical Pharmacology, 62, 567-572.
281. Niemi, M., Kivisto, K.T., Hofmann, U., Schwab, M., Eichelbaum, M. and Fromm, M.F. (2005) Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). British Journal of Clinical Pharmacology, 59, 602-604.
282. Kalliokoski, A., Neuvonen, M., Neuvonen, P.J. and Niemi, M. (2008) No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. British Journal of Clinical Pharmacology, 65, 78-86.
283. Miura, M., Satoh, S., Inoue, K., Kagaya, H., Saito, M., Inoue, T., Suzuki, T. and Habuchi, T. (2007) Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. European Journal of Clinical Pharmacology, 63, 1161-1169.
284. Xiang, X., Jada, S.R., Li, H.H., Fan, L., Tham, L.S., Wong, C.I., Lee, S.C., Lim, R., Zhou, Q.Y., Goh, B.C., Tan, E.H. and Chowbay, B. (2006) Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition inAsiancancerpatients. Pharmacogenetics and Genomics, 16, 683-691.
285. Oswald, S., Scheuch, E., Cascorbi, I. and Siegmund, W. (2006) A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 830, 143-150.
286. Bernsdorf, A., Giessmann, T., Modess, C., Wegner, D., Igelbrink, S., Hecker, U., Haenisch, S., Cascorbi, I., Terhaag, B. and Siegmund, W. (2006) Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. British Journal of Clinical Pharmacology, 61, 440-450.
287. Vormfelde, S.V., Toliat, M.R., Schirmer, M., Meineke, I., Nurnberg, P. and Brockmoller, J. (2007) The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 Allele*3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clinical Pharmacology and Therapeutics, 83, 815-817.